Search
Clinician Ordering Portal
Scientific evidence
AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for MOHS micrographic surgery: A report of the American Academy of Dermatology, American College of MOHS Surgery, American Society for Dermatologic Surgery Association, and the American Society for MOHS Surgery
Oct 2012
The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics.
Publication: J Am Acad Dermatol
Collaborative ocular oncology group report no. 1: prospective validation of a multi-gene prognostic assay in uveal melanoma
Aug 2012
This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk).
Publication: Ophthalmology
Uveal melanoma prognostication: from lesion size and cell type to molecular class
Jun 2012
To review the evidence for molecular genetic testing of uveal melanoma in the context of prognostic indicators of metastasis and tumour-related mortality.
Publication: Canadian Journal of Ophthalmology
Uveal melanoma: molecular pattern, clinical features, and radiation response
Apr 2012
To characterize the clinical spectrum of class 1 and class 2 uveal melanomas and their relationship with intraocular proton radiation response.
Publication: American Journal of Ophthalmology
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families
Apr 2012
BAP1 has been shown to be a target of both somatic alteration in high-risk ocular melanomas (OM) and germline inactivation in a few individuals from cancer-prone families. These findings suggest that constitutional BAP1 changes may predispose individuals to metastatic OM and that familial permeation of deleterious alleles could delineate a new cancer syndrome.
Publication: PLoS ONE
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Dec 2011
Objective: To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer.
Publication: Journal of Medical Genetics
Frequent mutation of BAP1 in metastasizing uveal melanomas
Dec 2010
Publication: Science
Mutations in GNA11 in uveal melanoma
Dec 2010
Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.
Publication: The New England Journal of Medicine
Genomic research in uveal melanoma
Dec 2010
Publication: Retinal Today
An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma
Jul 2010
Uveal (ocular) melanoma is an aggressive cance rthat often forms undetectable micrometastases before diagnosis of the primary tumor. These micrometastases later multiply to generate metastatic tumors that are resistant to therapy and are uniformly fatal. We have previously identified a gene expression profile derived from the primary tumor that is extremely accurate for identifying patients at high risk of metastatic disease.
Publication: Journal of Molecular Diagnostics
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Dec 2008
BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway. However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown. Here we report frequent somatic mutations in the heterotrimeric G protein α-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%).
Publication: Nature
Oncogenic mutations in GNAQ occur early in uveal melanoma
Sep 2008
Publication: Invest Ophthalmol Vis Sci